Serving the Society Since 1986
Advanced Search
Volume 28 Issue 2
April 2013
    Citation: Karen A O Martins, Travis K Warren, Sina Bavari. Characterization of a Putative Filovirus Vaccine: Virus-Like Particles .VIROLOGICA SINICA, 2013, 28(2) : 65-70.  http://dx.doi.org/10.1007/s12250-013-3306-9
    shu

    Characterization of a Putative Filovirus Vaccine: Virus-Like Particles

    cstr: 32224.14.s12250-013-3306-9

    • US Army Medical Research Institute of Infectious Diseases, 1425 Porter St., Fort Detrick, MD 21702, USA

    • Corresponding author: Karen A O Martins, karen.a.oconnell.ctr@us.army.mil
    • Received Date: 10 January 2013
      Accepted Date: 24 January 2013
      Available online: 01 April 2013

      Fund Project: ChemicalBiological Medical System-Joint Vaccine Acquisition Program (CBMS-JVAP) as well as the Defense Threat Reduction Agency (DTRA) A151 A.41ChemicalBiological Medical System-Joint Vaccine Acquisition Program (CBMS-JVAP) as well as the Defense Threat Reduction Agency (DTRA) CBM.VAXV.03.11.RD.009

    • Filoviruses are hemorrhagic fever viruses endemic to parts of Africa and the Philippines. Infection carries with it a mortality rate of up to 90% and currently there are no effective vaccines or therapeutics available to combat infection. However, the filovirus virus-like particles (VLP), which are currently under development, have been shown to be a promising vaccine candidate. They provide protection from infection in the mouse, guinea pig, and nonhuman primate models of infection, eliciting high anti-glycoprotein antibody titers and T cell responses to viral proteins. In this review, we will highlight the development of the filovirus VLP and describe the current understanding of VLP immunogenicity and correlates of protection.
    • 加载中

      1. World Health Organization. 2012a. Outbreak news. Ebola, Democratic Republic of the Congo. Wkly Epidemiol Rec, 87: 421.

      2. World Health Organization. 2012b. Outbreak news. Marburg haemorrhagic fever, Uganda. Wkly Epidemiol Rec, 87: 414.

      3. Basler C F, and Amarasinghe G K. 2009. Evasion of interferon responses by Ebola and Marburg viruses. J Interferon Cytokine Res, 29: 511-520.
          doi: 10.1089/jir.2009.0076

      4. Bavari S, Bosio C M, Wiegand E, Ruthel G, Will A B, Geisbert T W, Hevey M, Schmaljohn C, Schmaljohn A, and Aman M J. 2002. Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J Exp Med, 195: 593-602.
          doi: 10.1084/jem.20011500

      5. Bosio C M, Moore B D, Warfield K L, Ruthel G, Mohamadzadeh M, Aman M J, and Bavari S. 2004. Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology, 326: 280-287.
          doi: 10.1016/j.virol.2004.05.025

      6. Bosio C M, Aman M J, Grogan C, Hogan R, Ruthel G, Negley D, Mohamadzadeh M, Bavari S, and Schmaljohn A. 2003. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis, 188: 1630-1638.
          doi: 10.1086/jid.2003.188.issue-11

      7. Bradfute S B, Dye J M, Jr., and Bavari S. 2011. Filovirus vaccines. Hum Vaccin, 7: 701-711.
          doi: 10.4161/hv.7.6.15398

      8. Bray M, Davis K, Geisbert T, Schmaljohn C, and Huggins J. 1998. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis, 178: 651-661.
          doi: 10.1086/jid.1998.178.issue-3

      9. Cardenas W B, Loo Y M, Gale M, Jr., Hartman A L, Kimberlin C R, Martinez-Sobrido L, Saphire E O, and Basler C F. 2006. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol, 80: 5168-5178.
          doi: 10.1128/JVI.02199-05

      10. Chang T H, Kubota T, Matsuoka M, Jones S, Bradfute S B, Bray M, and Ozato K. 2009. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog, 5: e1000493.
          doi: 10.1371/journal.ppat.1000493

      11. Feldmann H, Klenk H D, and Sanchez A. 1993. Molecular biology and evolution of filoviruses. Arch Virol Suppl, 7: 81-100.
          doi: 10.1007/978-3-7091-9300-6

      12. Johnson R F, Bell P, and Harty R N. 2006. Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology. Virol J, 3: 31.
          doi: 10.1186/1743-422X-3-31

      13. Leung L W, Park M S, Martinez O, Valmas C, Lopez C B, and Basler C F. 2011. Ebolavirus VP35 suppresses IFN production from conventional but not plasmacytoid dendritic cells. Immunol Cell Biol, 89: 792-802.
          doi: 10.1038/icb.2010.169

      14. Licata J M, Johnson R F, Han Z, and Harty R N. 2004. Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J Virol, 78: 7344-7351.
          doi: 10.1128/JVI.78.14.7344-7351.2004

      15. Makino A, Yamayoshi S, Shinya K, Noda T, and Kawaoka Y. 2011. Identification of amino acids in Marburg virus VP40 that are important for virus-like particle budding. J Infect Dis, 204 Suppl 3: S871-877.

      16. Martinez O, Valmas C, and Basler C F. 2007. Ebola virus-like particle-induced activation of NF-kappaB and Erk signaling in human dendritic cells requires the glycoprotein mucin domain. Virology, 364: 342-354.
          doi: 10.1016/j.virol.2007.03.020

      17. Okumura A, Pitha P M, and Harty R N. 2008. ISG15 inhibits Ebola VP40 VLP budding in an L-domain-dependent manner by blocking Nedd4 ligase activity. Proc Natl Acad Sci U S A, 105: 3974-3979.
          doi: 10.1073/pnas.0710629105

      18. Sullivan N J, Martin J E, Graham B S, and Nabel G J. 2009. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol, 7: 393-400.
          doi: 10.1038/nrmicro2129

      19. Swenson D L, Warfield K L, Negley D L, Schmaljohn A, Aman M J, and Bavari S. 2005. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine, 23: 3033-3042.
          doi: 10.1016/j.vaccine.2004.11.070

      20. Swenson D L, Warfield K L, Kuehl K, Larsen T, Hevey M C, Schmaljohn A, Bavari S, and Aman M J. 2004. Generation of Marburg virus-like particles by co-expression of glycoprotein and matrix protein. FEMS Immunol Med Microbiol, 40: 27-31.
          doi: 10.1016/S0928-8244(03)00273-6

      21. Swenson D L, Wang D, Luo M, Warfield K L, Woraratanadharm J, Holman D H, Dong J Y, and Pratt W D. 2008. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin Vaccine Immunol, 15: 460-467.
          doi: 10.1128/CVI.00431-07

      22. Wahl-Jensen V, Kurz S K, Hazelton P R, Schnittler H J, Stroher U, Burton D R, and Feldmann H. 2005. Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. J Virol, 79: 2413-2419.
          doi: 10.1128/JVI.79.4.2413-2419.2005

      23. Wahl-Jensen V, Kurz S, Feldmann F, Buehler L K, Kindrachuk J, DeFilippis V, da Silva Correia J, Fruh K, Kuhn J H, Burton D R, and Feldmann H. 2011. Ebola virion attachment and entry into human macrophages profoundly effects early cellular gene expression. PLoS Negl Trop Dis, 5: e1359.
          doi: 10.1371/journal.pntd.0001359

      24. Wahl-Jensen V M, Afanasieva T A, Seebach J, Stroher U, Feldmann H, and Schnittler H J. 2005. Effects of Ebola virus glycoproteins on endothelial cell activation and barrier function. J Virol, 79: 10442-10450.
          doi: 10.1128/JVI.79.16.10442-10450.2005

      25. Warfield K L, Deal E M, and Bavari S. 2009. Filovirus infections. J Am Vet Med Assoc, 234: 1130-1139.
          doi: 10.2460/javma.234.9.1130

      26. Warfield K L, Swenson D L, Negley D L, Schmaljohn A L, Aman M J, and Bavari S. 2004. Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection. Vaccine, 22: 3495-3502.
          doi: 10.1016/j.vaccine.2004.01.063

      27. Warfield K L, Swenson D L, Olinger G G, Kalina W V, Aman M J, and Bavari S. 2007. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis, 196 Suppl 2: S430-437.

      28. Warfield K L, Bosio C M, Welcher B C, Deal E M, Mohamadzadeh M, Schmaljohn A, Aman M J, and Bavari S. 2003. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A, 100: 15889-15894.
          doi: 10.1073/pnas.2237038100

      29. Warfield K L, Olinger G, Deal E M, Swenson D L, Bailey M, Negley D L, Hart M K, and Bavari S. 2005. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol, 175: 1184-1191.
          doi: 10.4049/jimmunol.175.2.1184

      30. Warfield K L, Perkins J G, Swenson D L, Deal E M, Bosio C M, Aman M J, Yokoyama W M, Young H A, and Bavari S. 2004. Role of natural killer cells in innate protection against lethal ebola virus infection. J Exp Med, 200: 169-179.
          doi: 10.1084/jem.20032141

      31. Warfield K L, Posten N A, Swenson D L, Olinger G G, Esposito D, Gillette W K, Hopkins R F, Costantino J, Panchal R G, Hartley J L, Aman M J, and Bavari S. 2007. Filovirus-like particles produced in insect cells: immunogenicity and protection in rodents. J Infect Dis, 196 Suppl 2: S421-429.

      32. Yasuda J, Nakao M, Kawaoka Y, and Shida H. 2003. Nedd4 regulates egress of Ebola virus-like particles from host cells. J Virol, 77: 9987-9992.
          doi: 10.1128/JVI.77.18.9987-9992.2003

    • 加载中

    Figures(2)

    PDF

    Article Metrics

    Article views(6299) PDF downloads(12) Cited by()

    Related
    Proportional views

      Characterization of a Putative Filovirus Vaccine: Virus-Like Particles

        Corresponding author: Karen A O Martins, karen.a.oconnell.ctr@us.army.mil
      • US Army Medical Research Institute of Infectious Diseases, 1425 Porter St., Fort Detrick, MD 21702, USA
      • Received Date: 10 January 2013
      • Accepted Date: 24 January 2013
      Fund Project:  ChemicalBiological Medical System-Joint Vaccine Acquisition Program (CBMS-JVAP) as well as the Defense Threat Reduction Agency (DTRA) A151 A.41ChemicalBiological Medical System-Joint Vaccine Acquisition Program (CBMS-JVAP) as well as the Defense Threat Reduction Agency (DTRA) CBM.VAXV.03.11.RD.009

      Abstract: Filoviruses are hemorrhagic fever viruses endemic to parts of Africa and the Philippines. Infection carries with it a mortality rate of up to 90% and currently there are no effective vaccines or therapeutics available to combat infection. However, the filovirus virus-like particles (VLP), which are currently under development, have been shown to be a promising vaccine candidate. They provide protection from infection in the mouse, guinea pig, and nonhuman primate models of infection, eliciting high anti-glycoprotein antibody titers and T cell responses to viral proteins. In this review, we will highlight the development of the filovirus VLP and describe the current understanding of VLP immunogenicity and correlates of protection.

        HTML

      Filovirus Virus-Like Particles